# Xiamen Changrong Investment Management

> Xiamen Changrong Investment Management is a VC fund backing Biotechnology. See 12 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Xiamen, China
- Total investments: 12
- Last investment: Jan 2023
- Lead investor: 8%
- Last updated: Aug 2026
- Website: http://www.xmcrcapital.cn/

Xiamen Changrong Investment Management is a VC fund in Xiamen focused on Biotechnology and Medical. Xiamen Changrong Investment Management will invest in equity investments in innovative medicines, medical devices, artificial intelligence, semiconductors, new energy and education. Long-term financing is composed of experienced professionals in the industry. It has strong resource integration and fund management capabilities. Based on richexperience in capital operation and industry investment, it finds and supports the most outstanding entrepreneurial teams and enterprises with growth potential. The service model provides a series of services including capital operation, financial advisory, and industrial operation to comprehensively enhance the value of the entrepreneurial team and the enterprise.

## Contacts

5 contacts available for Xiamen Changrong Investment Management. Shizune tracks 4 team members at Xiamen Changrong Investment Management. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/xiamen-changrong-investment-management?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 42% |
| Medical | 4 | 33% |
| Health Care | 3 | 25% |
| Therapeutics | 2 | 17% |
| Pharmaceutical | 2 | 17% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 25% |
| Venture - Series Unknown | 3 | 25% |
| Series B | 2 | 17% |
| Seed | 1 | 8% |
| Pre-Seed | 1 | 8% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 6 | 50% |
| China | 5 | 42% |
| Malaysia | 1 | 8% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jiancheng Sun | Chief Adviser | 0 | — |
| Jiayu Cai | Managing Partner | 0 | — |
| Lin Sun | Executive Director | 1 | — |
| Wei Xie | Managing Partner | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Ling Siwei | Ling Siwei is a chip designer focusing on IoT communications. |  | Venture - Series Unknown | Jan 01, 2023 |  |
| NAKI Therapeutics | NAKI Therapeutics is a research-focused biopharmaceutical company developing Chimeric Antigen Receptor (CAR)-Natural Killer (NK) immunotherapy used to kill cancer cells effectively and safely compared to existing treatments. The company was founded in 2020 and is headquartered in Summit, New Jersey. |  | Venture - Series Unknown | Jan 01, 2023 |  |
| Amberstone Biosciences | Amberstone Biosciences discovers novel immunotherapies through innovative technologies and creative partnerships.Amberstone's focus is difficult targets requiring a unique mode-of-action and/or particular functional property, which are otherwise challenging for traditional approaches.These conventional limitations are overcome via atwo-pronged approach. First, we have demonstrated success with our microfluidics-powered AmberFlow drug-discovery platform. Second, our team of experts has keen insights in immuno-oncology and ample experience with single-cell assay biology. | $12M | Series A | Jan 03, 2022 |  |
| AceLink Therapeutics | AceLink Therapeutics is a startup biopharmaceutical company located in the San Francisco Bay Area. |  | Venture - Series Unknown | Jan 01, 2022 |  |
| Eubulus | Eubulus is an early-stage company focusing on building a platform technology for therapeutic enhancement. The company specializes in Proteolysis- targeting chimeras (PROTACSs). | $10M | Series A | Oct 14, 2021 |  |
| Anji Pharmaceuticals | Anji Pharmaceuticals is focused on tackling high-value targets validated by human genetics. We are exhaustive in our discovery and clinical efforts while nimble in our strategy and execution. We have assembled a world-class team of scientist entrepreneurs who are committed to accelerate innovative medicines in China and worldwide. | $70M | Series B | Sep 28, 2021 |  |
| VivaVision Biotech | VivaVision Biotech is a clinical-stage R&D biopharmaceutical company. | $46.2M | Series D | Apr 21, 2021 |  |
| Focus-X Therapeutics | Focus-X Therapeutics is a preclinical-stage biotechnology company focused on the radiopharmaceutical pipeline. They focus on unmet needs in cancer diagnosis and therapy by applying our theragnostic approach to solid tumors with a very low five-year survival rate. It brings its proprietary radioligand therapy (RLT) to precisely deliver alpha orbeta emitters to break down cancer cell DNA. | $1.5M | Pre-Seed | Sep 22, 2020 |  |
| Elgia Therapeutics | Elgia Therapeutics is a biotechnology company that specializes in novel approaches for the treatment of chronic inflammatory and fibrotic diseases. It specializes in the fields of healthcare, therapeutics, pharmaceutical, and medicine. It is creating innovative medicines for debilitating chronic diseases. It has discovered how metabolic stressdrives inflammation and fibrosis and has identified untapped protein targets for small molecule drug discovery. |  | Seed | Jun 15, 2020 |  |
| Viva Biotech | Viva Biotech is a Healthcare Start Up Based In Shanghai. | $30M |  | Jun 21, 2018 |  |

10 of 12 investments shown.

## Co-investors
- [Viva BioInnovator](https://shizune.co/investors/profile/viva-biotech) — VC Fund, 4 deals together
- Beida Biomedical Industry Fund — VC Fund, 2 deals together
- [AVIC Trust](https://shizune.co/investors/profile/avic-trust) — VC Fund, 1 deal together
- [Cenova Capital](https://shizune.co/investors/profile/cenova-capital-215e) — VC Fund, 1 deal together
- [Cenova](https://shizune.co/investors/profile/cenova-ventures) — VC Fund, 1 deal together
- CFS Capital — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Xiamen Changrong Investment Management invest in?

Xiamen Changrong Investment Management invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Venture - Series Unknown stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Xiamen Changrong Investment Management?

Public channels for Xiamen Changrong Investment Management include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Xiamen Changrong Investment Management?

The team at Xiamen Changrong Investment Management includes Jiancheng Sun (Chief Adviser), Jiayu Cai (Managing Partner) and Lin Sun (Executive Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co